Using comparative genomics to leverage animal models in the identification of cancer genes. Examples in prostate cancer

Cancer Genomics and Proteomics

Volumn 2, Issue 3, 2005, Pages 137-144

  Datta, Milton W ^a   Suckow, Mark A ^b   Twigger, Simon ^c   Pollard, Morris ^b   Jacob, Howard ^c   Tonellato, Peter J ^c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d PointOne System   (United States)

Author keywords

Animal models; Cancer genes; Comparative genomics; Prostate cancer

Indexed keywords

TUMOR MARKER;

BIOINFORMATICS; CANCER GENETICS; CANCER MODEL; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CHROMOSOME ANALYSIS; DIETARY INTAKE; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE IDENTIFICATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOMICS; HUMAN; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PREDICTION; PROSTATE CANCER; RAT; REVIEW; SYNTENY; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 20344368582     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Pennacchio LA: Insights from human/mouse genome comparisons. Mamm Genome 14(7): 429-436, 2003.
2. Gibbs RA et al: Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 428(6982): 493-521, 2004.
3. Waterston RH et al: Initial sequencing and comparative analysis of the mouse genome. Nature 420(6915): 520-562, 2002.
4. Rubin GM et al: Comparative genomics of the eukaryotes. Science 287(5461): 2204-2215, 2000.
5. Pickeral OK et al: Classical oncogenes and tumor suppressor genes: a comparative genomics perspective. Neoplasia 2(3): 280-286, 2000.
6. Makalowski W, Zhang J and Boguski MS: Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res 6(9): 846-857, 1996.
7. Katoh M: Comparative genomics on Wnt7a orthologs. Oncol Rep 13(4): 777-780, 2005.
8. Katoh M: Comparative genomics on Wnt8a and Wnt8b genes. Int J Oncol 26(4): 1129-1133, 2005.
9. Yanagitani N et al: Localization of a human lung adenocarcinoma susceptibility locus, possibly syntenic to the mouse Pas1 locus, in the vicinity of the D12S1034 locus on chromosome 12p11.2-p12.1. Carcinogenesis 23(7): 1177-1183, 2002.
10. Lastowska M et al: Regions syntenic to human 17q are gained in mouse and rat neuroblastoma. Genes Chromosomes Cancer 40(2): 158-163, 2004.
11. Corso C and Parry JM: Comparative genomic hybridization analysis of N-methyl-N′-nitrosoguanidine-induced rat gastrointestinal tumors discloses a cytogenetic fingerprint. Environ Mol Mutagen 43(1): 20-27, 2004.
12. Lee JS, Grisham JW and Thorgeirsson SS: Comparative functional genomics for identifying models of human cancer. Carcinogenesis, 2005.
13. Lee JS et al: Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36(12): 1306-1311, 2004.
14. Schlicht M et al: Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium. BMC Genomics 5(1): 58, 2004
15. Lucia MS et al: Workgroup I: rodent models of prostate cancer. Prostate 36(1): 49-55, 1998.
16. Waters DJ and Bostwick DG: The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res 17(3A): 1467-1470, 1997.
17. Pollard M and Wolter W: Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate 45(2): 101-105, 2000.
18. Pollard M, Wolter W and Sun L: Diet and the duration of testosterone-dependent prostate cancer in Lobund-Wistar rats. Cancer Lett 173(2): 127-131, 2001.
19. Weber KS et al: Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5alpha-reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague- Dawley rats. J Endocrinol 170(3): 591-599, 2001.
20. Di Cristofano A et al: Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27(2): 222-224, 2001.
21. Gao H et al: A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 101(49): 17204-17209, 2004.
22. Kim MJ et al: Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99(5): 2884-2889, 2002.
23. Kwabi-Addo B et al: Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98(20): 11563-11568, 2001.
24. Podsypanina K et al: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96(4): 1563-1568, 1999.
25. Tanaka M et al: Nkx3.1, a murine homolog of Drosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands. Dev Dyn 219(2): 248-260, 2000.
26. Powell WC et al: Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer. Curr Drug Targets 4(3): 263-279, 2003.
27. Harvell DM et al: Diet-gene interactions in estrogen-induced mammary carcinogenesis in the ACI rat. J Nutr 131(11 Suppl): 3087S-3091S, 2001.
28. Shull JD et al: Susceptibility to estrogen-induced mammary cancer segregates as an incompletely dominant phenotype in reciprocal crosses between the ACI and Copenhagen rat strains. Endocrinology 142(12): 5124-5130, 2001.
29. Shepel LA and Gould MN: The genetic components of susceptibility to breast cancer in the rat. Prog Exp Tumor Res 35: 158-169, 1999.
30. Lan H et al: Genetic loci controlling breast cancer susceptibility in the Wistar-Kyoto rat. Genetics 157(1): 331-339, 2001.
31. Gould KA et al: Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 168(4): 2113-2125, 2004.
32. Jiang F and Wang Z: Identification of androgen-responsive genes in the rat ventral prostate by complementary deoxyribonucleic acid subtraction and microarray. Endocrinology 144(4): 1257-1265.
33. Reyes N et al: Microarray analysis of diet-induced alterations in gene expression in the ACI rat prostate. Eur J Cancer Prev 11(Suppl 2): S37-42, 2002.
34. Reyes I et al: Aging-associated changes in gene expression in the ACI rat prostate: implications for carcinogenesis. Prostate 63(2): 169-186, 2005.
35. Desai KV et al: Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate. Mol Endocrinol 18(12): 2895-2907, 2004.
36. Strausberg RL: The Cancer Genome Anatomy Project: new resources for reading the molecular signatures of cancer. J Pathol 195(1): 31-40, 2001.
37. Etim A et al: ChromSorter PC: a database of chromosomal regions associated with human prostate cancer. BMC Genomics 5(1): 27, 2004.
38. Pollard M: Lobund-Wistar rat model of prostate cancer in man. Prostate 37(1): 1-4, 1998.
39. Pollard M, Woher W and Sun L: Prevention of induced prostate-related cancer by soy protein isolate/isoflavone-supplemented diet in Lobund-Wistar rats. In Vivo 14(3): 389-392, 2000.
40. Pollard M, Wolter W and Sun L: Diet and the duration of testosterone-dependent prostate cancer in Lobund-Wistar rats. Cancer Lett 173(2): 127-131, 2001.
41. Pollard M and Luckert PH: Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats. Nutr Cancer 28(1): 41-45, 1997.
42. Suckow MA, Wolter W and Pollard M: Susceptibility of Lobund-Wistar × Copenhagen hybrid rats to autochthonous prostate carcinogenesis. Prostate, 2005.
43. Gibbs M et al: Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 64(3): 776-787, 1999.
44. Berry R et al: Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 66(2): 539-546, 2000.
45. Badzioch M et al: Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators. J Med Genet 37(12): 947-949, 2000.
46. Porkka KP et al: RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes Chromosomes Cancer 39(1): 1-10, 2004.
47. Tsuchiya N et al: Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Am J Pathol 160(5): 1799-1806, 2002.
48. Tsuchiya N et al: Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 34(4): 363-371, 2002.
49. van Dekken H et al: Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest 83(6): 789-796, 2003.
50. Van Den Berg C et al: DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res 1(1): 11-18, 1995.
51. Balint I et al: Cloning and characterisation of the RBCC728/TRIM36 zinc-binding protein from the tumor suppressor gene region at chromosome 5q22.3. Gene 332: 45-50, 2004.
52. Chu LW et al: Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer 36(3): 303-312, 2003.
53. Hyytinen ER et al: Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 34(3): 306-312, 2002.
54. Wang Z, Lai FM and Zhang J: Analysis of loss of heterozygosity on chromosome 6 in human prostate carcinoma and prostatic intraepithelial neoplasia. Zhonghua Bing Li Xue Za Zhi 30(6): 414-417, 2001.
55. Dong JT: Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 20(3-4): 173-193, 2001.
56. Heidenreich B et al: Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur Urol 38(4): 475-482, 2000.
57. Merenmies J, Parada LF and Henkemeyer M: Receptor tyrosine kinase signaling in vascular development. Cell Growth Differ 8(1): 3-10, 1997.
58. Caine GJ et al: Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 33(10): 883-890, 2003.
59. Wurmbach JH et al: The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res 20(6D): 5217-5220, 2000.
60. Xu J et al: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20(2): 175-179, 1998.
61. Peters MA et al: Genetic linkage analysis of prostate cancer families to Xq27-28. Hum Hered 51(1-2): 107-113, 2001.
62. Kibel AS et al: Xq27-28 deletions in prostate carcinoma. Genes Chromosomes Cancer 37(4): 381-388, 2003.
63. Farnham JM et al: Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet 116(3): 179-185, 2005.
64. Gupta S et al: Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol 21(1): 106-112, 2003.
65. Saleem M et al: Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model. Clin Cancer Res 11(1): 147-153, 2005.
66. Rehman I et al: S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 91(4): 739-744, 2004.
67. Rehman I et al: Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Hum Pathol 35(11): 1385-1391, 2004.